Some people find that a light coating of coconut oil on the lips before sleep prevents the worst of the nighttime cracking
GLP-1 y libido Los GLP-1 se han asociado con cambios en el deseo sexual en algunos pacientes
Liraglutide, semaglutide and tirzepatide are incretin-based therapies currently approved by FDA for the management of obesity, while triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), the cagrilintide/semaglutide (CagriSema) 2.4 mg combination, high-dose oral semaglutide, and oral orforglipron are in advanced stages of development
Cystathionine beta-synthase deficiency causes fat loss in mice
Regular thyroid function tests under the supervision of a healthcare professional are recommended
From a clinical standpoint, the message is clear: - Yes to metabolic monitoring - Yes to awareness of glycemic risk - But no to avoiding statins out of fear of diabetes, especially in patients at high cardiovascular risk The real question isnt: Do statins cause diabetes? but rather: Does cardiovascular benefit outweigh metabolic risk? And once again, the answer is: yes
